<DOC>
	<DOCNO>NCT02695004</DOCNO>
	<brief_summary>This study evaluate safety , tolerability PK DKF-310 IM injection healthy male volunteer .</brief_summary>
	<brief_title>Safety , Tolerability Pharmacokinetics DKF-310 ( ( Donepezil ) .</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Donepezil</mesh_term>
	<criteria>Men age 19 50 year Body weight 55 90 kg BMI 18.0 27.0 Voluntarily sign informed consent form Eligible accord screen test result Available follow dropout Clinically significant disorder medical history hepatic , renal , neurological , respiratory , endocrine , hematooncologic , cardiovascular , urological psychiatric disease Hypersensitivity donepezil , piperidine derivative drug SBP &lt; 100 mmHg &gt; 150 mmHg , DBP &lt; 60 mmHg &gt; 100 mmHg Skin muscle disorder history surgery injection site AST ALT &gt; 1.5xULN ; QT/QTcB interval &gt; 450 ms History positive result drug abuse Prescribed drug herbal medicine within 2 week , overthecounter drug vitamin within 1 week Participated clinical trial within 3 month Donated whole blood within 2 month apheresis within 1 month , transfusion within 1 month Alcohol consumption &gt; 21 units/week Smoked &gt; 10 cigarettes/day within 3 month Caffeinecontaining food Not eligible due reason investigator 's discretion</criteria>
	<gender>Male</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>